癌症的发生、扩散、转移和耐药通常与基因、基因组和表观遗传层面的改变有关。过去的几十年里，在遗传和表观遗传调控的研究背景下，随着新技术的研发和平台的搭建，例如深度测序、ChIP-seq、ATAC-seq、Hi-C、单细胞测序、类器官培养、遗传工程等，我们更加深入地了解了癌症如何启动、扩散和转移。专刊旨在发表这一迅速发展研究领域的最新进展和最具洞察力的见解。
JGG 诚挚欢迎您为本专刊投稿，Reviews、Research articles以及Resource articles等多种形式的稿件均可。专刊接受的论文稿件将免费出版发表。如需进一步了解，请联系我们：[email protected]。期待收到您的稿件！
Special Issue on Cancer Genetics, Genomics and Epigenetics
The Journal of Genetics and Genomics (JGG ) is now inviting submissions for a special issue (to be published in June 2021) on the topics of cancer genetics, genomics and epigenetics. Dr. Hongbin Ji, from Shanghai Institute of Biochemistry and Cell Biology, CAS Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences; Dr. Ceshi Chen, from Kunming Institute of Zoology, Chinese Academy of Sciences; and Dr. Ying Hu, from School of Life Science and Technology, Harbin Institute of Technology are the guest editors for this issue.
Cancer initiation, progression, metastases and drug resistance are frequently associated with the alterations at genetic, genomic and epigenetic levels. Great efforts into a better understanding of cancer genetics and epigenetics have significantly shaped current therapeutics in clinic. In past decades, new techniques and platforms, such as deep sequencing, ChIP-seq, ATAC-seq, Hi-C as well as single cell-seq, organoind culture, and genetically engineered mouse model have been developed to gain deep insights into how cancer initiates, progresses and metastasizes in the context of genetic and epigenetic regulation. This special issue aims to provide a timely update on the current understanding and insightful mechanistic findings of this rapidly developing field.
Reviews, Research articles and Resource articles are all welcome. The portfolio will be open for incoming manuscripts until January 22, 2021. Accepted submissions will be published free of charge.
Manuscripts should be submitted online at http://ees.elsevier.com/jgg. Please indicate that the submission is for this special issue.
For further information, please contact us: [email protected]. We look forward to receiving your submission.
